[ad_1]
OR phase 1/2 clinical trial of a vaccine candidate product (CoronaVac) involved more than 700 healthy volunteers, ages 18 to 59, recruited from China between 16 April and 05 of May.
“The vaccine appeared to be safe and well tolerated at all doses tested. The most reported side effect was pain at the injection site. injection“reads the information released by the Lancet.
14 days after the final dose, detected “robust responses” of antibodies after two injections vaccine candidate, 14 days apart, even with the lowest dose tested.
Vaccine-induced antibody levels were lower than those seen in people who were infected and recovered from illness COVID-19-19, caused by the new coronavirus, but researchers say they still hope the vaccine can provide protection against the virus.
OR objective The main objective was to evaluate the immune response and the safety of the vaccine. The study was not designed to evaluate the effectiveness of prevention infection by SARS–CoV-2.
Results of the initial phase clinical trial of the whole virus-based vaccine candidate inactivated do SARS–CoV-2 (CoronaVac) were published in The Lancet Infectious Diseases, revealing that the formulation appears safe and induces an antibody response in healthy people.
Antibody responses can be induced within 28 days after the first immunization by administering two doses of the candidate vaccine 14 days apart.
The study also identified the ideal dose to generate the best antibody response, taking into account side effects and production capacity, which will be further studied. in detail in other trials already in progress.
Scientists believe that CoronaVac can provide protection enough against a COVID-19-19, based on experience with other vaccines and data from preclinical studies in monkeys.
The study was not designed Evaluating the effectiveness and results of phase 3 studies will be crucial in determining whether the immune response generated by the CoronaVac enough to protect against infection by SARS–CoV-2.
“In addition, the persistence of the antibody response should be verified in future studies to determine the duration of any protection“, refers in the document.
More studies will be needed to test the candidate vaccine in other age groups, as well as in people with pre-existing diseases.
“Our findings show that CoronaVac It is able to induce a rapid antibody response within four weeks after immunization, administering two doses of the vaccine within 14 days. We believe this makes the vaccine suitable for emergency use during pandemic. In the long term, when the risk of COVID-19-19 is lower, our results suggest that giving two doses one month apart instead of two weeks may be more appropriate to induce stronger and potentially longer-lasting immune responses, “he explained. Fengcai Zhu, co-author of the study, from the Provincial Center for Disease Control and Prevention of Jiangsu, Nanjingin China, defending the need for more studies.
CoronaVac is one of 48 candidate vaccines for COVID-19-19 what are they nowadays in clinical trials. It is a chemically complete viral vaccine. inactivated, based on a strain of SARS–CoV-2 that was originally isolated from a patient in China.
A pandemic from COVID-19-19 caused at least 1,328,048 deaths as a result of more than 55 million cases of infection around the world, according to a report by the French agency AFP.
Always be the first to know.
Follow the chosen site for the fourth consecutive year Consumer Choice.
Download our free app.
[ad_2]
